NASDAQ:DARE Daré Bioscience (DARE) Stock Forecast, Price & News $1.01 +0.03 (+3.06%) (As of 05/30/2023 ET) Add Compare Share Share Today's Range$0.96▼$1.0250-Day Range$0.97▼$1.0652-Week Range$0.82▼$1.47Volume266,849 shsAverage Volume259,522 shsMarket Capitalization$87.15 millionP/E RatioN/ADividend YieldN/APrice Target$7.00 ProfileProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial MediaProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial Media Daré Bioscience MarketRank™ ForecastAnalyst RatingBuy3.00 Rating ScoreUpside/Downside593.1% Upside$7.00 Price TargetShort InterestHealthy0.44% of Shares Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.69Based on 3 Articles This WeekInsider TradingN/AProj. Earnings GrowthDecreasingFrom ($0.33) to ($0.41) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.1.95 out of 5 starsMedical Sector695th out of 1,009 stocksPharmaceutical Preparations Industry352nd out of 494 stocks 3.5 Analyst's Opinion Consensus RatingDaré Bioscience has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 4 buy ratings, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $7.00, Daré Bioscience has a forecasted upside of 593.1% from its current price of $1.01.Amount of Analyst CoverageDaré Bioscience has only been the subject of 1 research reports in the past 90 days. Previous Next 5.0 Short Interest Percentage of Shares Shorted0.44% of the outstanding shares of Daré Bioscience have been sold short.Short Interest Ratio / Days to CoverDaré Bioscience has a short interest ratio ("days to cover") of 2, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Daré Bioscience has recently decreased by 25.91%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldDaré Bioscience does not currently pay a dividend.Dividend GrowthDaré Bioscience does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for DARE. Previous Next 2.0 News and Social Media Coverage News SentimentDaré Bioscience has a news sentiment score of 0.69. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.News Coverage This WeekMarketBeat has tracked 3 news articles for Daré Bioscience this week, compared to 2 articles on an average week.Search InterestOnly 5 people have searched for DARE on MarketBeat in the last 30 days. This is a decrease of -29% compared to the previous 30 days.MarketBeat FollowsOnly 3 people have added Daré Bioscience to their MarketBeat watchlist in the last 30 days. This is a decrease of -50% compared to the previous 30 days. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Daré Bioscience insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 4.00% of the stock of Daré Bioscience is held by insiders.Percentage Held by InstitutionsOnly 9.19% of the stock of Daré Bioscience is held by institutions. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for Daré Bioscience are expected to decrease in the coming year, from ($0.33) to ($0.41) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Daré Bioscience is -2.81, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Daré Bioscience is -2.81, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioDaré Bioscience has a P/B Ratio of 7.77. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Daré Bioscience (NASDAQ:DARE) StockDaré Bioscience, Inc. operates as a healthcare company, which engages in the development and commercialization of pharmaceutical products in women's reproductive health. Its products include Ovaprene and Topical Sildenafil. The company was founded by Sabrina Martucci Johnson, Lisa Walters-Hoffert and Roger L. Hawley in 2015 and is headquartered in San Diego, CA.Read More Receive DARE Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Daré Bioscience and its competitors with MarketBeat's FREE daily newsletter. Email Address DARE Stock News HeadlinesMay 25, 2023 | msn.comThe Dare Brings Back Early-2000s NYC Rock for 12 Joyless Minutes on ‘The Sex EP’May 17, 2023 | americanbankingnews.comFinancial Contrast: IVERIC bio (NASDAQ:ISEE) and Daré Bioscience (NASDAQ:DARE)May 30, 2023 | Legacy Research (Affiliate) (Ad)The “Amazon Secret Royalty Program” Can Help Anyone Retire Like RoyaltyA unique type of investment could help you make more money than you will need for the rest of your life. It’s what we call the “Amazon secret royalty program.” It’s an income stream that allows you to collect $1,000s… $10,000s… or more every year! Learn how to collect your first payout before June 13th.May 16, 2023 | finance.yahoo.comDaré Bioscience, Inc. (NASDAQ:DARE) Q1 2023 Earnings Call TranscriptMay 16, 2023 | yahoo.comEverybody Wants a Piece of The DareMay 16, 2023 | americanbankingnews.comFY2027 Earnings Estimate for Daré Bioscience, Inc. (NASDAQ:DARE) Issued By HC WainwrightMay 13, 2023 | markets.businessinsider.comMaxim Group Reaffirms Their Buy Rating on Daré Bioscience (DARE)May 13, 2023 | msn.comHC Wainwright & Co. Reiterates Dare Bioscience (DARE) Buy RecommendationMay 30, 2023 | Legacy Research (Affiliate) (Ad)The “Amazon Secret Royalty Program” Can Help Anyone Retire Like RoyaltyA unique type of investment could help you make more money than you will need for the rest of your life. It’s what we call the “Amazon secret royalty program.” It’s an income stream that allows you to collect $1,000s… $10,000s… or more every year! Learn how to collect your first payout before June 13th.May 12, 2023 | markets.businessinsider.comH.C. Wainwright Remains a Buy on Daré Bioscience (DARE)May 12, 2023 | marketwatch.comDare Bioscience Reports First Quarter 2023 Financial Results and Provides a Company UpdateMay 11, 2023 | finanznachrichten.deDaré Bioscience, Inc.: Daré Bioscience Reports First Quarter 2023 Financial Results and Provides a Company UpdateMay 11, 2023 | msn.comRecap: Dare Bioscience Q1 EarningsMay 11, 2023 | finance.yahoo.comDaré Bioscience Reports First Quarter 2023 Financial Results and Provides a Company UpdateMay 10, 2023 | msn.comEarnings Outlook For Dare BioscienceMay 9, 2023 | americanbankingnews.comDaré Bioscience (DARE) to Release Earnings on ThursdayMay 5, 2023 | msn.comDare County residents receive N.C Governor’s Volunteer Service AwardsMay 4, 2023 | finance.yahoo.comDaré Bioscience to Host First Quarter 2023 Financial Results and Company Update Conference Call and Webcast on May 11, 2023April 21, 2023 | americanbankingnews.comShort Interest in Daré Bioscience, Inc. (NASDAQ:DARE) Grows By 16.8%April 20, 2023 | nytimes.comTrack Covid-19 in Dare County, North CarolinaApril 20, 2023 | finance.yahoo.comDaré Bioscience Announces Initiation of Subject Enrollment in a Phase 1 Thermography Study to Support Pharmacodynamic and Pharmacokinetic Characterization of Sildenafil Cream, 3.6%April 19, 2023 | finance.yahoo.comDavid Friend, Ph.D., Chief Scientific Officer of Daré Bioscience, Inc., to Present at the Global Pharma & Drug Delivery Summit 2023 to be held April 24-26, 2023 in Frankfurt, GermanyApril 18, 2023 | finance.yahoo.comDaré Bioscience Announces Publication of Positive Safety and Acceptability Data from Phase 1 Clinical Trial that Support the Potential of DARE-HRT1 Intravaginal Ring as a New Menopausal Hormone TherapyApril 17, 2023 | finance.yahoo.comDaré Bioscience to Participate in Xpectives.Health SUMMIT Innovations in Women’s Health Business ConferenceApril 17, 2023 | finance.yahoo.comDaré Bioscience to Participate in Xpectives.Health SUMMIT Innovations in Women’s Health Business ConferenceApril 5, 2023 | finance.yahoo.comDaré Bioscience, Inc. (NASDAQ:DARE) Q4 2022 Earnings Call TranscriptApril 5, 2023 | americanbankingnews.comDaré Bioscience, Inc. to Post FY2027 Earnings of $0.80 Per Share, HC Wainwright Forecasts (NASDAQ:DARE)See More Headlines View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart Receive DARE Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Daré Bioscience and its competitors with MarketBeat's FREE daily newsletter. Email Address DARE Company Calendar Last Earnings3/30/2023Today5/30/2023Next Earnings (Estimated)8/08/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:DARE CUSIPN/A CIK1401914 Webwww.darebioscience.com Phone(858) 926-7655Fax617-494-1544Employees16Year FoundedN/APrice Target and Rating Average Stock Price Forecast$7.00 High Stock Price Forecast$7.00 Low Stock Price Forecast$7.00 Forecasted Upside/Downside+612.3%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage4 Analysts Profitability EPS (Most Recent Fiscal Year)($0.36) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-30,950,000.00 Net MarginsN/A Pretax Margin-305.92% Return on Equity-162.16% Return on Assets-69.54% Debt Debt-to-Equity RatioN/A Current Ratio1.21 Quick Ratio1.21 Sales & Book Value Annual Sales$10 million Price / Sales8.48 Cash FlowN/A Price / Cash FlowN/A Book Value$0.13 per share Price / Book7.56Miscellaneous Outstanding Shares86,290,000Free Float82,834,000Market Cap$84.81 million OptionableNot Optionable Beta1.20 Key ExecutivesSabrina Martucci JohnsonPresident, CEO, Secretary & DirectorMark WaltersVice President-OperationsLisa Walters-HoffertChief Financial OfficerChristine MauckMedical DirectorDavid FriendChief Scientific OfficerKey CompetitorsRVL PharmaceuticalsNASDAQ:RVLPImmunicNASDAQ:IMUXApplied TherapeuticsNASDAQ:APLTOcuphire PharmaNASDAQ:OCUPXilio TherapeuticsNASDAQ:XLOView All CompetitorsInstitutional OwnershipState Street CorpBought 21,600 shares on 5/16/2023Ownership: 0.287%Jane Street Group LLCBought 53,180 shares on 5/16/2023Ownership: 0.087%BlackRock Inc.Sold 89,952 shares on 5/12/2023Ownership: 0.726%Renaissance Technologies LLCBought 68,366 shares on 5/12/2023Ownership: 0.660%Virtu Financial LLCSold 44,988 shares on 5/1/2023Ownership: 0.038%View All Institutional Transactions DARE Stock - Frequently Asked Questions Should I buy or sell Daré Bioscience stock right now? 4 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Daré Bioscience in the last twelve months. There are currently 4 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" DARE shares. View DARE analyst ratings or view top-rated stocks. What is Daré Bioscience's stock price forecast for 2023? 4 Wall Street research analysts have issued twelve-month price objectives for Daré Bioscience's stock. Their DARE share price forecasts range from $7.00 to $7.00. On average, they anticipate the company's stock price to reach $7.00 in the next twelve months. This suggests a possible upside of 612.3% from the stock's current price. View analysts price targets for DARE or view top-rated stocks among Wall Street analysts. How have DARE shares performed in 2023? Daré Bioscience's stock was trading at $0.83 at the beginning of the year. Since then, DARE stock has increased by 18.4% and is now trading at $0.9828. View the best growth stocks for 2023 here. Are investors shorting Daré Bioscience? Daré Bioscience saw a drop in short interest in the month of May. As of May 15th, there was short interest totaling 378,600 shares, a drop of 25.9% from the April 30th total of 511,000 shares. Based on an average trading volume of 191,300 shares, the days-to-cover ratio is currently 2.0 days. View Daré Bioscience's Short Interest. When is Daré Bioscience's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Tuesday, August 8th 2023. View our DARE earnings forecast. How were Daré Bioscience's earnings last quarter? Daré Bioscience, Inc. (NASDAQ:DARE) posted its earnings results on Thursday, March, 30th. The biotechnology company reported ($0.19) earnings per share for the quarter, missing the consensus estimate of ($0.15) by $0.04. What other stocks do shareholders of Daré Bioscience own? Based on aggregate information from My MarketBeat watchlists, some companies that other Daré Bioscience investors own include FuelCell Energy (FCEL), Inovio Pharmaceuticals (INO), VBI Vaccines (VBIV), Vaxart (VXRT), Tonix Pharmaceuticals (TNXP), Matinas BioPharma (MTNB), Novavax (NVAX), Gilead Sciences (GILD), SCYNEXIS (SCYX) and Sorrento Therapeutics (SRNE). What is Daré Bioscience's stock symbol? Daré Bioscience trades on the NASDAQ under the ticker symbol "DARE." Who are Daré Bioscience's major shareholders? Daré Bioscience's stock is owned by a number of retail and institutional investors. Top institutional shareholders include BlackRock Inc. (0.73%), Renaissance Technologies LLC (0.66%), State Street Corp (0.29%), Jane Street Group LLC (0.09%) and Virtu Financial LLC (0.04%). View institutional ownership trends. How do I buy shares of Daré Bioscience? Shares of DARE stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Daré Bioscience's stock price today? One share of DARE stock can currently be purchased for approximately $0.98. How much money does Daré Bioscience make? Daré Bioscience (NASDAQ:DARE) has a market capitalization of $84.81 million and generates $10 million in revenue each year. The biotechnology company earns $-30,950,000.00 in net income (profit) each year or ($0.36) on an earnings per share basis. How can I contact Daré Bioscience? Daré Bioscience's mailing address is 3655 NOBEL DRIVE SUITE 260, SAN DIEGO CA, 92122. The official website for the company is www.darebioscience.com. The biotechnology company can be reached via phone at (858) 926-7655, via email at innovations@darebioscience.com, or via fax at 617-494-1544. This page (NASDAQ:DARE) was last updated on 5/30/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Daré Bioscience, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.